CALGB 9840 : Phase III study of weekly paclitaxel via 1-h infusion vs standard 3-h infusion every third week in the treament of metastatic breast cancer, with trastuzumab for HER2+ metastatic breast cancer (MBC), and randomized for trastuzumab for HER2 normal MBC

• SEIDMAN AD

収録刊行物

• Proc Am Soc Clin Oncol

  Proc Am Soc Clin Oncol 22 512-, 2004

詳細情報

• CRID: 1570009750438996224
• NII論文ID: 10018644199
• データソース種別:
  • CiNii Articles